Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported in part by educational grants from Celgene Corporation, Genentech, Lilly USA, LLC, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, and Seattle Genetics, Inc.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

17th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma

17th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma


Chair

Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, NY

Program Committee

Sundar Jagannath, MD
The Tisch Cancer Institute
Mount Sinai School of Medicine
The Mount Sinai Medical Center
New York, NY
  Charles Schiffer, MD
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, MI
  William G. Weirda, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, TX

Faculty

Ranjana Advani, MD
Stanford Cancer Institute
Stanford School of Medicine
Stanford, CA

Nancy Bartlett, MD
Washington University School of Medicine
St. Louis, MO
 
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
West Hollywood, CA
 
Donald Berry, PhD
University of Texas MD Anderson Cancer Center
Houston, TX
 
Jennifer Brown, MD, PhD

Dana Farber Cancer Institute
Harvard Medical School
Boston, MA
 
Patrick Brown, MD

Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, MD

James Bussel, MD
Weill Cornell Medical College
New York, NY
 
Bruce Cheson, MD

Georgetown Lombardi Comprehensive Cancer Center
Washington, DC

Nicholas Chiorazzi, MD
Weill Cornell Medical College
New York, NY
 
Daniel DeAngelo, MD, PhD

Dana Farber Cancer Institute
Boston, MA
 
Harry Erba, MD

University of Alabama Birmingham School of Medicine
Birmingham, AL

Eric Feldman, MD
Weill Cornell Medical College
New York, NY
 
Alessandra Ferrajoli, MD

University of Texas MD Anderson Cancer Center
Houston, TX
 
Jonathan Friedberg, MD, MMsc

James P. Wilmont Cancer Center
University of Rochester Medical Center
Rochester, NY

Randy Gascoyne, MD
BC Cancer Agency
Vancouver, BC, Canada
 
Andre Goy, MD

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, NJ
 
Paul Hamlin, MD

Memorial Sloan Kettering Cancer Center
New York, NY

Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
New York, NY
  Virginia Klemik, MD
Memorial Sloan Kettering Cancer Center
New York, NY
 
Thomas Kipps, MD, PhD

UCSD Moores Cancer Center
La Jolla, CA

Ola Landgren, MD
National Cancer Institute
Bethesda, MD

Ross Levine, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Michael Mauro, MD
Oregon Health and Science University
Portland, OR

Ari Melnick, MD
Weill Cornell Medical College
New York, NY

Ruben Mesa, MD, FACP
Mayo Clinic Cancer Center
Scottsdale, AZ
 
Craig Moskowitz, MD

Memorial Sloan Kettering Cancer Center
New York, NY
 
Nikhil Munshi, MD

Dana Farber Cancer Institute
Harvard Medical School
Boston, MA

Daniel O. Persky, MD
Yale Cancer Center
New Haven, CT

Lauren Pinter-Brown, MD, FACP
Geffen School of Medicine at UCLA
Los Angeles, CA
 
Pierluigi Porcu, MD

The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital
Richard Solove Research Institute
Columbus, OH
 
Richard Silver, MD

Weill Cornell Medical College
New York, NY
 
David Steensma, MD

Dana Farber Cancer Center
Harvard Medical School
Boston, MA

Richard Stone, MD
Harvard Medical School
Boston, MA
 
Moshe Talpaz, MD

University of Michigan Comprehensive Cancer Center
Ann Arbor, MI

Joachim Yahalom, MD
Memorial Sloan Kettering Cancer Center
New York, NY
 
Anas Younes, MD
The University of Texas MD Anderson Cancer Center
Houston, TX

Faculty and Staff Disclosures

The following individuals have relevant financial relationships with commercial interests to disclose:

Ranjana Advani, MD – Grant/Research Support – Allos Therapeutics, Seattle Genetics; Nancy Bartlett, MD – Paid Travel Expenses (ASCO Poster Presentation) – Seattle Genetics; James Berenson, MD – Grant/Research Support – Amgen, Novartis, Medtronic, Onyx, Millennium; Consultant: Onyx, Millennium, Amgen, Medtronic; Speaker’s Bureau – Onyx, Millenium, Amgen, Medtronic; Donald Berry PhD – Consultant – Berry Consultants, LLC; Stock/Shareholder – Co-owner of Berry Consultants, LLC; Jennifer Brown, MD, PhD – Grant/Research Support – Genzyme (now sanofi-aventis); Consultant – Genentech, Emergent, sanofi-aventis, Celgene, Onyx; James Bussel, MD – Grant/Research Support – Amgen, Cangene, GlaxoSmithKline, Genzyme, IgG of America, Immunomedics, Ligand, Eisai Inc, Shionogi, Sysmex; Consultant/Ad Board – Amgen, GlaxoSmithKline, Ligand, Shionogi, Symphogen, Eisai, Inc; Stock/Shareholder – Amgen, GlaxoSmithKline;  Bruce Cheson, MD – Consultant – Genentech, Celgene; Nicholas Chiorazzi, MD – Grant/Research Support: Pharmacyclics; Stock/Shareholder – Kinemed, Inc.; Daniel DeAngelo, MD, PhD – Consultant – Amgen; Harry Erba, MD – Grant/Research Support – Novartis, , Celator, GenzymeMillennium; Speaker’s Bureau – Celgene, Novartis, Incyte; Alessandra Ferrajoli, MD – Grant/Research Support – Celgene, GlaxoSmithKline; Other Support (Advisory Board) – Celgene, Pharmacyclics; Jonathan Friedberg, MD – Consultant – Genentech, Bayer, Seattle Genetics; Other Support (Data and Safety Monitoring): Lilly; Randy Gascoyne, MD, FRCPC – Grant/Research Support – Seattle Genetics, Roche Canada; Consultant – Seattle Genetics, Celgene, Janssen, Genentech, Roche; Speaker’s Bureau – Seattle Genetics; Andre Goy, MD – Clinical Trial Support Through Institutions; Speaker’s Bureau – Millennium; Advisory Board – Millennium, Celgene, Pharmacyclics, Johnson & Johnson, Seattle Genetics, Pfizer; Paul Hamlin, MD – Grant/Research Support – Spectrum, GlaxoSmithKline, Pfizer, Seattle Genetics; Consultant – Genentech, Gilead, Spectrum; Steven Horwitz, MD – Grant/Research Support – Celgene, Allos, Seattle Genetics, Infinity, Kyowa, Millennium; Consultant – Celgene, Allos, Seattle Genetics, Bristol Myers Squibb, Genzyme, Kyowa, Johnson & Johnson, Janssen, Millennium; Sundar Jagannath, MD – Consultant – Merck, Celgene, Millennium; Thomas Kipps, MD, PhD – Grant/Research Support – Abbott, Celgene, Genentech, Pharmacyclics, AstraZeneca, Amgen, Medimmude, Gilead; Consultant – Onyx; Stock/Shareholder – Eclipse Tx, Ingenica; Michael Mauro, MD – Grant/Research Support – Novartis, Bristol Myers Squibb, Ariad; Consultant – Novartis, Bristol Myers Squibb, Ariad, Pfizer; Ruben Mesa, MD, FACP – Research Support – Inyte, Celgene, Gilead, Infinity, Lilly, NS Pharma; Ari Melnick, MD – Grant/Research Support – NCI, Leukemia and Lymphoma Society; Consultant – Celgene; Speaker’s Bureau – Genentech; Craig Moskowitz, MD – Grant/Research Support – Seattle Genetics, Roche, GlaxoSmithKline, Plexxikon, Cephalon; Consultant – Seattle Genetics, Roche, GlaxoSmithKline; Nikhil Munshi, MD – Consultant – Celgene, Merck, Millenium, Onyx; Daniel Persky, MD – Grant/Research Support – Merck; Lauren Pinter-Brown, MD, FACP – Consultant – Spectrum; Pierluigi Porcu, MD – Grant/Research Support – Millennium; Consultant – Hospira, Elorac; Charles Schiffer, MD – Grant/Research Support – Ariad, Celgene, Ambit, Bristol Myers Squibb; Consultant – Eisai, Teva, Celgene, Novartis, Bristol Myers Squibb; Richard Silver, MD – Grant/Research Support – Merck; Clinical Trial Investigator – Interferon in treatment in early phase myleofibrosis; David Steensma, MD – Consultant – Amgen, Array, Biopharma, Boehringer Ingelheim, Celgene; Richard Stone, MD – Grant/Research Support – Novartis; Consultant – Teva, Seattle Genetics, Amgen; Other Support – Sunesis (OSMB), Amgen (Steering Committee); Moshe Talpaz, MD – Grant/Research Support – Novartis, Ariad, Bristol Myers Squibb, sanofi-aventis, Incyte; Consultant – Novartis, Ariad, Bristol Myers Squibb, Teva; Speaker’s Bureau – Novartis, Ariad; William Wierda, MD, PhD – Grant/Research Support – Abbott, GlaxoSmithKline, Genentech/Roche; Consultant – Celgene, Genentech/Roche, Merck, sanofi-aventis; Speaker’s Bureau – Celgene, GlaxoSmithKline, Genentech/Roche; Anas Younes, MD – Grant/Research Support – Seattle Genetics, Millennium, Johnson & Johnson, Gilead, Novartis; Consultant – Seattle Genetics, Millennium, ISIS, Novartis; Andrew Zelenetz, MD – Research – Roche, GlaxoSmithKline, Genentech; Consulting – Seattle Genetics, sanofi-aventis USA, GlaxoSmithKline, Gilead, Cephalon, Celgene; Other – Scientific Advisor – Cancer Genetics
 
The following individuals have no relevant financial relationships with commercial interests to disclose: Patrick Brown, MD; Eric Feldman, MD; Virginia Klimek, MD, Ola Landgren, MD, PhD; Ross Levine, MD; Joachim Yahalom, MD
 
Physicians’ Education Resource®, LLC Planning Staff – Ann C. Lichti, CCMEP, Tristan Nelsen, MNM, CMP and Susan Peck, PhD.

Off-Label Disclosure and Disclaimer
This CME activity will contain discussions about off-label/unapproved uses of drugs including but not limited to brentuximab vedotin, carfilzomib, pomalidomide, doxorubicin, dexamethasone, bortezomib, bendamustine, melphalan, lenalidomide, delanzomib, ibrutinib, idelalisib, rituximab for ITP, romiplostim and eltrombopag for pediatric ITP, E5501 (avatrombopag maleate) for ITP, ABT‑199, IPI-145, SCDT 2980s, ofatumumab, aurora kinase inhibitors, GS-1101, PCYC-32765, IP2101, ibritumomab tiuxetan, interferon in MPNs, rigosertib, clofarabine for MDS, ponatinib, blinatumomab, azacitidine, decitabine and clofarbine.
 
For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed or consult the Physicians’ Desk Reference. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
 
Disclaimer
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.






Become a Member

Forgot Password?
Filter By